Novo Nordisk A/S, a leading global healthcare company, has announced the progress of its share repurchase program on May 17, 2024. The program, which began on February 6, 2024, is set to repurchase up to DKK 20 billion worth of shares over a 12-month period. As part of this initiative, a specific share repurchase plan was initiated on May 6, 2024, with the intention to buy back B shares for an amount up to DKK 2.2 billion between May 7, 2024, and August 5, 2024. Since the start of this plan, Novo Nordisk has conducted several transactions, resulting in the repurchase of 242,000 B shares at an average price of DKK 871.78 to DKK 917.73, amounting to a total of DKK 218,194,459. Additionally, transactions related to the company's incentive programs have led to a...Show More

Novo Nordisk A/S, a leading global healthcare company, has announced the progress of its share repurchase program on May 17, 2024. The program, which began on February 6, 2024, is set to repurchase up to DKK 20 billion worth of shares over a 12-month period. As part of this initiative, a specific share repurchase plan was initiated on May 6, 2024, with the intention to buy back B shares for an amount up to DKK 2.2 billion between May 7, 2024, and August 5, 2024. Since the start of this plan, Novo Nordisk has conducted several transactions, resulting in the repurchase of 242,000 B shares at an average price of DKK 871.78 to DKK 917.73, amounting to a total of DKK 218,194,459. Additionally, transactions related to the company's incentive programs have led to a net transfer of 63,694 B shares during the same period. These transactions are separate from the Safe Harbour repurchase program. As a result of these activities, Novo Nordisk now holds 10,341,814 B shares as treasury shares, which is 0.2% of the share capital. The company has repurchased a total of 8,976,250 B shares at an average price of DKK 862.94 per share since February 6, 2024, totaling DKK 7,745,929,232. Novo Nordisk, founded in 1923 and headquartered in Denmark, is committed to defeating serious chronic diseases and employs approximately 66,000 people worldwide.